Autolus Therapeutics Plc Growth Comparisons

Select each growth Category to receive further Information

Select the Comparisons :

Growth Rates ▼

Select the Ratio:

None▼

Growth Rates ▼

None▼

Download as CSV

AUTL Revenue Growth Rate Comparisons	Company	Industry	Sector	S&P 500
Y / Y Revenue Growth (Q2 MRQ)	-	1.92 %	5.99 %	4.7 %
Q / Q Revenue Growth (Q2 MRQ)	132.94 %	2.91 %	5.87 %	4.11 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM)	-	3.24 %	5.75 %	%
Sequential Revenue Growth (for 12 months ending Q2 TTM)	232.19 %	0.61 %	1.39 %	1.17 %
Revenue 5 Year Average Growth	-	6.38 %	8.21 %	7.56 %

AUTL's Growth Comparisons in II. Quarter 2025

Autolus Therapeutics Plc reported top-line of $ 21 millions in the second quarter 2025, compare to $ 0 millions in the same quarter a year ago. Revenues in the Biotechnology & Pharmaceuticals industry grew by 1.92%, while the top-line in the Healthcare sector increased by 5.99%, and overall market improved by 4.7% from the second quarter 2024.

Company's sequential Revenue growth rate was impressive 132.94% from the first quarter. Average yearly sales growth for Autolus Therapeutics Plc is %, while S & P 500's average annual sales growth is 7.56% over the five years, including only Businesses with the second quarter 2025 financial reports.

AUTL Growth Rates by Company's Segments

Segment Name	Y / Y	Sequential
Product revenue net	-30.04 %	132.94 %
Product revenue net United States of America	-30.04 %	-
Product Revenue net Reportable Segment	-	-
Total	-	132.94 %

Growth Rates of AUTL's Income in the second quarter 2025

AUTL Operating Income Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Operating Income Change (Q2 MRQ)	-	82.75 %	57.81 %	10.32 %
Sequential Operating Income Change (Q2 MRQ)	-	109.91 %	15.93 %	4.92 %
Y / Y Operating Income Growth (Q2 TTM)	-	-	69.09 %	3.22 %
Sequential Operating Income Growth (Q2 TTM)	-	22.29 %	12.78 %	0.95 %
Operating Income 5 Year Avg. Change	-	-	-2.02 %	9.12 %

Income from Cont. Ops. Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ)	-	-	161.62 %	6.6 %
Sequential Income from Cont. Ops. Change (Q2 MRQ)	-	-	7.49 %	6.18 %
Y / Y Income from Cont. Ops. Change (Q2 TTM)	-	-	167.85 %	9.77 %
Sequential Income from Cont. Ops. Change (Q2 TTM)	-	244.6 %	24.84 %	1.93 %
Income from Cont. Ops. 5 Year Avg. Change	-	-	-9.4 %	9.11 %

AUTL Net Income Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Net Income Growth (Q2 MRQ)	-	-	152.67 %	8.18 %
Q / Q Net Income Growth (Q2 MRQ)	-	-	6.95 %	6.45 %
Y / Y Net Income Change (Q2 TTM)	-	-	70.08 %	9.28 %
Sequential Net Income Change (Q2 TTM)	-	364.98 %	23.27 %	2.32 %
Net Income 5 Year Avg. Growth	-	-	-8.86 %	8.67 %

AUTL's EPS Growth Rates

EPS from Cont. Ops. Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ)	-	-	161.62 %	6.6 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ)	-	-	7.49 %	6.18 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM)	-	-	-	-
Sequential EPS from Cont. Ops. Change (Q2 TTM)	-	-	-	-37.11 %
EPS from Cont. Ops. 5 Year Avg. Growth	-	-	-9.4 %	9.11 %

AUTL EPS Net Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y EPS Net Growth (Q2 MRQ)	-	-	152.67 %	9.11 %
Q / Q EPS Net Growth (Q2 MRQ)	-	-	6.95 %	6.45 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM)	-	-	-	-40.33 %
Sequential EPS Net Change (for 12 months ending Q2 TTM)	-	-	-	-37.11 %
EPS Net 5 Year Avg. Change	-	-	-8.86 %	8.67 %

Autolus Therapeutics Plc reported bottom-line of $ -0.18 in the second quarter, compare to $ -0.22 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry grew by 1.92%, while Healthcare sector increased by 152.67%, and overall market improved by 8.18%.

The Company's sequential EPS growth rate was very impressive 132.94% from the first quarter. Average yearly income per share growth for Autolus Therapeutics Plc is %, while S & P 500's average annual income per share growth is 8.67% over the five years, including only Businesses with the second quarter 2025 earnings results.

AUTL Cash Flow Growth Rates

Free Cash Flow Growth Rates	Company	Industry	Sector	S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ)	-	-	27 %	-8.64 %
Sequential Free Cash Flow Change (Q2 MRQ)	-	-	48.41 %	1421.99 %
Y / Y Free Cash Flow Change (Q2 TTM)	-	61.35 %	19.3 %	-5.86 %
Sequential Free Cash Flow Change (Q2 TTM)	-	-15.64 %	4.11 %	-0.64 %
Free Cash Flow 5 Year Avg. Change	-	-17.05 %	4.62 %	8.25 %

Net Cash Flow Growth Rates	Company	Industry	Sector	S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ)	-	-	-	-
Sequential Net Cash Flow Change (Q2 MRQ)	-	-	-	-
Y / Y Net Cash Flow Change (Q2 TTM)	-	-	-	-
Sequential Net Cash Flow Change (Q2 TTM)	-	-87.61 %	-	-
Net Cash Flow 5 Year Avg. Change	-	-	-19.62 %	0.44 %

Capital Expenditures	Company	Industry	Sector	S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ)	765.28 %	-54.36 %	3.21 %	17.12 %
Sequential Capital Expenditures Change (Q2 MRQ)	-11.72 %	-41.06 %	2.58 %	10.67 %
Y / Y Capital Expenditures Change (Q2 TTM)	300.86 %	-9.97 %	7.51 %	16.6 %
Sequential Capital Expenditures Change (Q2 TTM)	15.13 %	-12.64 %	0.68 %	4.06 %
Capital Expenditures 5 Year Avg. Change	-	4.59 %	8.03 %	7.55 %

Note
To view Detail Information & Trends click on Individual Category. Example: Y / Y Revenue Change (MRQ) or To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table. Example: Industry Sector S&P 500 For explanation of terms visit: Glossary

Valuation Comparisons

Management Effectiveness

Financial Strength

Efficiency

Dividend Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.